Activated T cells and cytokine-induced CD3+ CD56+ killer cells

Annals of Hematology

Volumn 74, Issue 2, 1997, Pages 51-56

  Schmidt Wolf, G D ^a   Negrin, R S ^b   Schmidt Wolf, I G H ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cytokine induced killer cells; Immunotherapy; T cells

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; CANCER CELL DESTRUCTION; CANCER IMMUNOTHERAPY; CYTOTOXICITY; EFFECTOR CELL; HUMAN; KILLER CELL; LYMPHOKINE ACTIVATED KILLER CELL; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE;

ANTIGENS, CD3; ANTIGENS, CD56; HUMANS; KILLER CELLS; KILLER CELLS, LYMPHOKINE-ACTIVATED;

EID: 0031045290     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770050257     Document Type: Short Survey

References (49)

1. Yron Y, Wood TA, Spiess PJ et al. (1980) In vitro growth of murine T cells. V. The isolation and growth of lymphoid cell-sinfiltrating syngeneic solid tumors. J Immunol 125:238-245
2. Lotze MT, Line BR, Mathisen DJ et al. (1980) The in vivo distribution of autologous human and murine lymphoid cells-grown in T cell growth factor (TCGF) Implications for the adoptive immunotherapy of tumors. J Immunol 125:1487-1493
3. Lotzova E, Savary CA, Herberman RB (1987) Induction of NK cell activity against fresh human leukemia in culture with interleukin-2. J Immunol 138:2718-2727
4. Fierro MT, Liao X-S, Lusso P, Bonferroni M, Matera L, CesanoA, Lista P, Arione R, Forni G, Foa R (1988) In vitro and in vivo susceptibility of human leukemic cells to lymphokine-activated killer activity. Leukemia 2:50-54
5. Alder A, Chervenick PA, Whiteside TL, Lotzova E, Herberman RB (1988) Interleukin 2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients. I. Feasibility of LAK generation in adult patients with active disease and in remission. Blood 71:709-716
6. Archimbaud E. Bailly M, Dore J-F (1991) Inducibility of lymphokine activated killer (LAK) cells in patients with acute myelogenous leukaemia in complete remission and its clinical relevance. Br J Haematol 77:328-334
7. Rosenberg SA (1992) The immunotherapy and gene therapy of cancer. J Clin Oncol 10:180-199
8. Oshimi K, Oshimi V, Motoji T, Kobayashi S, Mizoguchi H (1985) Lysis of leukemia and lymphoma cells by autologous and allogeneic interferon-activaied blood mononuclear cells. Blood 61:790-798
9. Oshimi K, Oshimi Y, Satake M, Mizoguchi H (1985) Natural-killer mediated lysis of normal and malignant target cells, and its regulation by monocytes. J Exp Med 162:472-486
10. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine-activated killer cell phenomenon. I. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes J Exp Med 155:1823-1841
11. Grimm EA, Ramsey KM, Mazumder A, Wilson DJ, Djeu JY, Rosenberg SA (1983) Lymphokine-activated killer cellphenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. J Exp Med 157:884-897
12. Grimm EA, Robb RJ, Roth JA, Neckers LA, Lachman LB, Wilson DJ, Rosenberg SA (1983) Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells. J Exp Med 158:1356-1361
13. + lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL-2)-induced activated killer-(AK) cells. J Immunol 134:802-807
14. Ortaldo JR, Herberman RB (1984) Heterogeneity of natural killer cells. Annu Rev Immunol 2:359-394
15. Phillips JH, Lanier LL (1986) Dissection of the LAK phenomenon: relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J Exp Med 164:814-825
16. Ballas ZK, Rasmussen W (1987) LAK cells: characterization of LAK precursors and susceptible target cells within the murine thymus. J Immunol 139:3542-3549
17. Sawada H, Abo T, Sugawara S, Kumagai K (1988) Prerequisite for the induction of LAK cells from T lymphocytes. J Immunol 140:3668-3673
18. Rosenberg SA, Lotze MT, Muul LM (1977) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889-897
19. Lanier LL, Ruitenberg JL, Phillips JH (1988) Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes. J Immunol 141:3478-3485
20. Ritz J, Schmidt RE, Michon J, Hercend T, Schlossman SF (1988) Characterization of functional surface structures on human natural killer cells. Adv Immunol 42:181-211
21. Ortaldo JR, Mason A, Overton R (1986) Lymphokine-activated killer cells. Analysis of progenitors and effectors. J Exp Med 164:1193-1205
22. + cells: examinationof morphology, functions, T cell receptor rearrangement, and pore-forming protein expression. Cell Immunol 136:486-495
23. Mule JJ, Shu S, Schwarz SL, Rosenberg SA (1984) Adoptive immunotherapy of established pulmonary metastases with LAKcells and recombinant IL2. Science 225:1487-1489
24. Rosenberg SA (1985) Lymphokine-activated killer cells. A new approach to immunotherapy of cancer. J Natl Cancer Inst 75:595-603
25. Rosenberg SA, Lotze MT, Muul LM, Leitmen S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp C, Simpson C, Reichert CM (1985) Observations on thesystemic administration of autologous LAK cells and rIL2 to patients with metastatic cancer. N Engl J Med 313:1485-1492
26. Lafreniere R, Rosenberg SA (1985) Successful immunotherapy of murine experimental hepatic metastases with LAK cells and rIL2. Cancer Res 45:3735-3741
27. Takahashi H, Nakada T, Puisieux I (1993) Inhibition of human colon cancer growth by antibody-directed human LAK cells in SCID mice. Science 259:1460-1463
28. Faber LM, van Luxemburg-Heijs SAP, Willemze R, Falkenbug, JHF (1992) Generation of leukemia-reactive cylotoxic Tlymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. J Exp Med 176:1283-1289
29. Rosenberg SA, Spiess PS, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318-1321
30. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Sion P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter C, Bock S, Schwartzenhuber D, Wei JP, White DE (1988) Use of tumor-infiltrating lymphocytes and IL2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 319:1676-1680
31. Whiteside TL (1990) Human tumor-infiltrating lymphocytes and their characterisation. In: Lotzova E, Herberman RB (eds) Interleukin-2 and killer cells in cancer. CRC Press, Boca Raton, pp 133
32. Curti BD, Longo DL, Ochoa AC, Conlon KC, Smith JW, Alvord WG et al. (1993) Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2. J Clin Oncol 11:652-660
33. Schmidt-Wolf IGH, Negrin RS, Kiem HP, Blume KG, Weissman IL (1991) Use of a SCID mouse/human lymphoma model to evaluate cytokine induced killer cells with potent antitumor cell activity. J Exp Med 174:139-149
34. Schmidt-Wolf IGH, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, Weissman IL, Negrin RS (1993) Phenotypic characterization and identification of effector cells involved in tumor recognition of cytokine-induced killer cells. Exp Hematol 21:1673-1679
35. Schmidt-Wolf IGH, Lefterova P, Johnston V, Scheffold C, Csipai M, Mehta B, Tsuruo T, Huhn D, Blume KG, Negrin RS (1996) Sensitivity of multidrug-resistant tumor cell lines to immunoloaic effector cells. Cell Immunol 169:85-90
36. + cells derived from T cells with potent in vivo antitumor activity in mice with SCID. J Immunol 1687-1696
37. Schmidt-Wolf IGH, Grimm B, Brandt K, Lefterova P, Johnston V, Scheffold C, Huhn D, Serke S (1995) Propagation of large numbers of cells of a human mixed-lineage T-lymphoid/myeloid. Br J Haematol 90:512-517
38. Schmidt-Wolf IGH, Lefterova P, Johnston V, Neubauer A, Huhn D, Negrin R, Blume KG (1994) Propagation of T cells with NK cell marker. Br J Haematol 87:453-458
39. Scheffold C, Brandt K, Johnston V, Lefterova P, Huhn D, Neubauer A, Negrin RS, Schmidt-Wolf IGH (1995) Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloic leukemia. Bone Marrow Transplant 15:33-39
40. Hauch M, Gazzola MV, Small T et al (1990) Anti-leukemia potential of interleukin-2-activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. Blood 75:2250-2262
41. Notter M, Ludwig W-D, Bremer S, Thiel E (1993) Selective targeting of human lymphokine-activated killer cells by CD3 monoclonal antibody against the interferon-inducible high-affinity Fc gamma RI receptor (CD64) on autologous acute-myeloid leukemic blast cells. Blood 82:3113-3124
42. + killer cells. Blood 86:3493-3499
43. Csipai M, Lefterova P, Finke S, Johnston V, Scheffold C, Huhn D, Schmidt-Wolf IGH (1996) Effects of interleukin-7 on proliferation of tumor and immunologic effector cells. Cancer Res Ther Contr (in press)
44. Schmidt-Wolf IGH, Neubauer A, Finke S, Csipai M, Wittig B, Huhn D (1994) Interleukin-7 gene therapy for patients with metastatic colon cancer, renal cell cancer, malignant melanoma or lymphoma. Hum Gene Ther 5:1161-1169
45. Finke S, Trojaneck B, Lefterova P, Csipai M, Wagner E, Neubauer A, Huhn D, Wittig B, Schmidt-Wolf IGH (1995) Enhancement of antitumor cytotoxicity of human immunologic effector cells by transfection with the interleukin-7 gene. Blood (submitted)
46. Songsivilai S, Lachmann PJ (1990) Bispecific antibody: a tool for diagnosis and treatment of disease. Clin Exp Immunol 79:315-321
47. Bolhuis RLH, Sturm E, Braakman E (1991) T cell targeting in cancer therapy. Cancer Immunol Immunother 34:1-8
48. Kaneko T, Fusauch Y, Kakui Y, Okumura K, Mizoguchi H, Oshimi K (1994) Cytotoxicity of cytokine-induced killer cells coated with bispecific antibody against acute myeloid leukemia cells. Leukemia Lymphoma 14:219-229
49. Kaneko T, Fusauchi Y, Kakui Y, Masuda M, Akahosi M, Teramura M, Motoji T, Okumura K, Mizoguchi H, Oshimi K (1993) A bispecific antibody enhances cytokine-induced killer-mediated cytolysis of autologous acute myeloid leukemia cells. Blood 81:1333-1341